IMMUNOGLOBULIN V<sub>H</sub> DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES*

BY HIROMI KUBAGAWA, MITSUFUMI MAYUMI, JOHN F. KEARNEY, AND MAX D. COOPER

From the Cellular Immunobiology Unit of the Tumor Institute, Departments of Pediatrics and Microbiology, University of Alabama in Birmingham, Birmingham, Alabama 35294

The heavy and light chains of immunoglobulins (Ig) consist of two distinct regions: variable and constant. Variable regions, which determine the antibody specificity and idiotypic determinants, are further divided into three hypervariable regions and four relatively invariant, so-called framework, regions (1, 2). The variable regions of both heavy chains (V<sub>H</sub>) and light chains (V<sub>L</sub>) have been divided into subgroups based upon similarities between amino acid sequences in their framework regions. For human Ig, three major V<sub>H</sub> subgroups have been characterized on the basis of amino acid sequences of the aminoterminal 20 residues within the first framework region (2). One set of goat antibodies specific for each human V<sub>H</sub> subgroup has been prepared by selective adsorption and was found to be useful in typing secreted and membrane-bound Ig on B cells (3).

Evidence from studies (4-8) using anti-idiotypic antibodies has suggested that T cells and their antigen-specific, soluble factors might possess Ig-like idiotypic determinants. V<sub>H</sub> allotypic determinants have also been demonstrable on rabbit T cells by several groups (9, 10) and not by others (11-15). Antibodies against V<sub>H</sub> framework regions of the mouse myeloma protein MOPC-315, which cross-react with other mouse Ig regardless of their antibody specificity, class, subclass, subgroup, or allotype (16), may inhibit T cell function (17-19) and cross-react with soluble factors of T cells (20, 21). The molecular nature of antigen receptors on T lymphocytes, however, is still controversial. Recent studies (22, 23) using recombinant DNA techniques have suggested that antigen-specific helper or killer T cell clones may not use the Ig-joining and constant gene segments.

We prepared monoclonal hybridoma antibodies against V<sub>H</sub> fragments isolated from human IgM myeloma proteins with the hope of using these to analyze the products of normal or abnormal B and T cells. This paper describes the preparation and characterization of four such monoclonal anti-human V<sub>H</sub> antibodies. Our studies

---

* Supported by grants CA 16673 and CA 13148, awarded by the National Cancer Institute, and grants AI 14782 and AI 00338, awarded by the National Institute of Allergy and Infectious Diseases.

1. Abbreviations used in this paper: anti-C<sub>H</sub>, antibodies to heavy chain isotype; anti-C<sub>L</sub>, antibodies to light chain type; anti-Id, antibodies to idiotypic determinants; AP, alkaline phosphatase; BSB, borate saline buffer; cIg, cytoplasmic immunoglobulins; ELISA, enzyme-linked immunosorbent assay; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; HAT, hypoxanthine-aminopterin-thymidine; NTCB, 2-nitro-5-thiocyanobenzoic acid; PBL, peripheral blood lymphocytes; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; RITC, rhodamine isothiocyanate; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; sIg, surface immunoglobulins; V<sub>H</sub>, variable portions of immunoglobulin heavy chains; V<sub>L</sub>, variable portions of immunoglobulin light chains; V<sub>H</sub>, variable portions of μ heavy chains.
show that monoclonal V_{H}-specific antibodies are more readily prepared using isolated V_{H} fragments as immunogens and that these antibodies are specific for "hidden" determinants not exposed on intact Ig molecules.

Materials and Methods

Mice. Inbred BALB/c and (BALB/c × C57BL/6)F_{1} hybrid (CB6) mice were obtained from The Jackson Laboratory, Bar Harbor, ME, and used at 2–3 mo of age.

Isolation of V_{H} Fragments from Human IgM Paraproteins. IgM paraproteins were isolated from the sera of patients with Waldenström's macroglobulinemia or multiple myeloma by repeated euglobulin precipitation against distilled water, followed by gel filtration on a Sepharose 6B (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, NJ) column equilibrated with borate saline buffer, pH 8.3, ionic strength, 0.1 (BSB). The elution peak containing pentameric IgM was pooled, concentrated, and dialyzed against 0.1 M Tris-HCl buffer, pH 8.6, containing 2 mM EDTA. Some of the IgM paraproteins with known V_{H} and V_{L} subgroups were kindly provided by Dr. J. D. Capra (University of Texas, Dallas, TX). The purity of isolated IgM was tested by immunoelectrophoresis and double diffusion in agar, using antisera or antibodies specific for normal whole serum proteins, IgM, IgG, and IgA.

V_{H} fragments were isolated from IgM paraproteins by a modification of methods described by Rodwell and Karush (24). The amount of 2-nitro-3-thiocyanobenzoic acid (NTCB; Eastman Kodak Co., Rochester, NY) for cyanylation of the sulfhydryl groups of reduced IgM was used at a ratio of NTCB/IgM of 5 mg/100 mg. This ratio corresponded approximately to a five-fold molar excess of NTCB to protein-associated sulfhydryl groups. NTCB was used in this study without purification, although its melting point was 2–3°C lower than the reported value (25). The reaction mixture containing the cleavage products was lyophilized, dissolved in 3 ml of 5 M guanidine-HCl, pH 7.0, containing 2 mM EDTA, and then applied to a calibrated Sephadex G-150 column equilibrated with the same denaturant. The fractions containing V_{H} fragments, which eluted after the light chain peak, were collected, dialyzed against BSB to remove guanidine, and then purified further by passage through a Sepharose 4B column to which the homologous light chains were coupled (26). The bound V_{H} fragments were eluted from the column by 0.05 M glycine-HCl buffer, pH 2.8, neutralized with BSB, and then dialyzed against saline before use for immunization.

IgG, IgA, and IgD myeloma proteins were also isolated by salt fractionation, DEAE ion-exchange cellulose column chromatography, and Sepharose 6B gel filtration, as described elsewhere (27). IgE myeloma protein (PS, V_{H}, V_{L}) was a gift from Dr. K. Ishizaka (Johns Hopkins University, Baltimore, MD). Heavy and light chains were isolated by partial reduction and alkylation of purified myeloma Ig or pooled normal IgG followed by separation on Sephadex G-200 in 5 M guanidine-HCl, pH 7.0. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed in slabs of 5–20% acrylamide gradient gels in Tris-HCl buffer, as described by Laemmli (28).

Immunization. BALB/c and CB6 mice were immunized 6–7 times with 80–100 µg of purified V_{H} fragments, isolated µ chains, or intact myeloma proteins at 3- or 7-d intervals. In some cases, mice were immunized with V_{H} fragments at 14-d intervals for the first four injections, rested for 2 mo, and then immunized again at 7-d intervals for the last three injections. The first injection was always given with complete Freund's adjuvant (Difco Laboratories, Detroit, MI), the second in incomplete Freund's adjuvant, and the remainder in saline. All mice were immunized subcutaneously in footpads, inguinal, and axillary regions. Mice were killed 1 d after the last immunization, and the cells from the draining popliteal, inguinal, axillary, and para-aortic lymph nodes were prepared by gentle teasing and used for fusion.

Preparation of Monoclonal Anti-V_{H} Antibodies. Lymph node cells from immunized mice were fused with an equal number of P3-X63-Ag.8.653 cells, a non-Ig-producing variant of the hypoxanthine-aminopterin-thymidine (HAT)-sensitive BALB/c myeloma cell line P3-X63-Ag.8, by using polyethylene glycol 4000 (Fisher Scientific Company, Atlanta, GA), as described previously (29, 30). The cells were plated into 24-well plates (Costar, Data Packaging, Cambridge, MA) at a cell concentration of 2 × 10^{9} cells/ml in the HAT medium. 2–3 wk after fusion, culture supernatants from the wells were screened for antibody activity against the
various immunogens by an enzyme-linked immunosorbent assay (ELISA) (31). Affinity-purified goat anti-mouse κ and λ antibodies labeled with alkaline phosphatase (AP) were used as second-step reagents (31). After detecting hybrid-containing wells with antibody activities, the antibody specificities were tested further by ELISA against a panel of 8–12 different purified antigens, including Vικ fragments, various intact Ig, isolated heavy or light chains, and F(ab')2 fragments of normal IgG. Hybridomas that secreted antibodies reacting with common or homologous Vι determinants in this initial screening were then chosen for further study and recloned by limiting dilution on syngeneic normal mouse peritoneal exudate feeder cells. The Ig isotypes of the hybridoma antibodies were also determined at this stage using AP-labeled goat antibodies specific for mouse μ, γ1, γ2a, γ2b, γλ, α, κ, and λ chain determinants, as described elsewhere (32).

10–30 million cells from positive reclones were injected intraperitoneally into syngeneic mice previously primed with pristane (Aldrich, Milwaukee WI). Ascites were harvested, and monoclonal anti-Vι antibodies were purified from the ascites fluid by absorption to Sepharose 4B coupled with the appropriate antigens. Bound antibodies were eluted from the column by 0.05 M glycine-HCl buffer, pH 2.8. In some experiments, antibodies precipitated from hybridoma ascites by 60% saturation of ammonium sulfate were used as the anti-Vι antibody preparation after dialysis against BSB.

Radioimmunoassay. The specificity of monoclonal anti-Vι antibodies was examined by using a solid-phase, direct binding radioimmunoassay. 96-well polyvinyl plastic plates (Dynatech Laboratories, Inc., Alexandria, VA) were coated with anti-Vι antibodies (10 μg/ml) by overnight incubation at room temperature. After washing and saturating free sites on the plastic plates with 1% bovine serum albumin (Sigma Chemical Co., St. Louis, MO) in BSB, various concentrations of purified antigens, including intact Ig and isolated heavy or light chains, were added to the antibody-coated wells in triplicate and incubated for 4 h at 37°C. After washing out unbound antigens, 125I-labeled monoclonal hybridoma antibodies specific for human μ, γ, κ, or λ determinants (~10^5 cpm/100 μl) were added to each well and incubated for 4 h at 37°C. Unbound radioactivity was washed out with BSB, and the wells were counted in a gamma counter. All monoclonal hybridoma antibodies used for 125I-labeling were purified by affinity chromatography.

Cell Preparation. Peripheral blood lymphocytes (PBL) were isolated from normal adults by Ficoll-Hypaque density gradient centrifugation. Bone marrow specimens were obtained with informed consent from normal volunteers or patients with monoclonal gammopathies by aspiration and with parental consent from fetuses aborted for reasons of maternal health by suction curetage. Mononuclear cells were isolated from bone marrow samples by previously described methods (33). Gestational age was estimated by measuring long bone length (34). Normal tonsillar and splenic tissues were dispersed into a single cell suspension by gentle teasing in phosphate-buffered saline (PBS) containing 5% fetal calf serum (FCS; Flow Laboratories Inc., Rockville, MD.). The use of these materials for research purposes was approved by the University of Alabama in Birmingham committee on human experimentation. After washing with PBS containing 5% FCS, the cells were resuspended in RPMI 1640 supplemented with 20% FCS and incubated in plastic plates for 1 h at 37°C to remove adherent cells and cytophilic IgG. T cells were enriched from PBL by rosette formation with 2-aminoethyl-isothiouronium bromide (AET; Sigma Chemical Co.)-treated sheep erythrocytes and density gradient separation (35). In some experiments, PBL or enriched T cells were cultured in the presence of phytohemagglutinin M (PHA, 5 μl/ml) at a cell concentration of 5 × 10^5 cells/ml of RPMI 1640 containing 20% FCS for 2 d at 37°C under 5% CO2.

Immunofluorescent Analysis of Cells. The characteristics of Vι+ cells were determined by two-color immunofluorescence as previously described (27, 33). For surface staining, 10^6 viable cells were incubated with 10 μl of monoclonal anti-Vι antibodies (0.5 mg/ml) for 20 min at 4°C, washed, and stained with 10 μl of rhodamine-isothiocyanate (RITC)-labeled F(ab')2γ fragments of rabbit anti-mouse Ig antibodies (0.4 mg/ml; F/P ratio, 2.1). After washing out free conjugates, the cells were counterstained with 10 μl of fluorescein isothiocyanate (FITC)-labeled goat anti-human Ig antibodies (0.5 mg/ml; F/P ratio, 3.5). FITC-labeled goat antibodies specific for human Ig isotype (μ, γ, α, κ) were also used for counterstaining. After washing, the doubly stained cells were cytocentrifuged onto glass slides, fixed in 95% ethanol-5% acetic acid
at -20°C, rehydrated in PBS, and then mounted in Elvanol. Smears of unstained cells were similarly prepared by cytocentrifugation, fixed, and stained with one-fifth the concentration of the same reagents. Both affinity-purified antibodies for labeling with RITC (anti-mouse Ig) or FITC (anti-human Ig or anti-isotype) were extensively absorbed with normal pooled human Ig and human IgM myeloma proteins or with normal pooled mouse Ig and mouse IgM myeloma proteins, respectively. Pre-B cells, B lymphocytes, and plasma cells expressing V_H determinants were identified as previously described (27, 33).

Results

Purification of V_\mu Fragments by Affinity Chromatography. V_\mu fragments were isolated from human IgM myeloma proteins by the following steps: (a) reduction of interdisulfide bonds of IgM molecules with dithiothreitol, (b) cyanylation of their sulfhydryl groups with NTCB, and (c) cleavage of IgM molecules at the amino side of the cyanylated residues by alkaline pH, as described by Rodwell and Karush (24). The isolation profile of such a reaction mixture, as determined by Sephadex G-150 gel filtration in 5 M guanidine-HCl, was essentially the same as their reported profile on Sephacryl S-200 gel filtration. The V_\mu peak, however, contained a few additional protein fragments that migrated between the light chain and V_\mu bands on SDS-PAGE (Fig. 1). These protein fragments (or side products) did not decrease in quantity, even after reduction of the molar ratio of NTCB/IgM from a 25- to a 5-fold excess (data not shown). Subsequent cleavage was done at a five-fold excess.

When the V_\mu fragments containing side products from a Sephadex G-150 column were applied to a Sepharose 4B column coupled with the homologous light chains, only the V_\mu fragments bound to the light chain column. The elution of V_\mu fragments by acid buffer afforded highly purified V_\mu fragments (Fig. 1, lane 1).

These findings indicate that V_\mu fragments isolated by selective cyanylation and cleavage can bind to the homologous light chains under physiological conditions, and this provides an efficient method of purifying isolated V_\mu fragments.

Production of Monoclonal Anti-V_H Antibodies. In our initial attempts to prepare monoclonal antibodies to common V_H determinants, we immunized mice with intact Ig molecules or isolated heavy chains. The culture supernatants from 6-24% of wells,
containing lymph node cells derived hybridomas from mice immunized with intact IgMx (SA, VH, and Vk, untyped), IgDa (010), or IgEA (PS, VHII, VMI), showed antibody activity against the immunizing antigens (Table I). 40–70% of these positive wells contained antibody specific for the heavy chain isotype of the immunogen (anti-CH); i.e., anti-μ, anti-δ, or anti-ε. About 10–30% had antibody specific for the light chain type of the homologous immunogen (anti-CL), i.e., anti-k or anti-λ. The remaining positive wells produced antibodies reactive only with the homologous intact myeloma proteins, probably anti-idiotypic (anti-Id). None of the monoclonal antibodies prepared in this way were reactive with isolated VH fragments or with multiple heavy chain isotypes. Similarly, the culture supernatants of hybridomas derived from mice immunized with the μ chain (007, VHII) showed mostly anti-μ activities, except for one well that reacted only with the homologous intact myeloma protein; no anti-VH antibodies were detected.

In contrast to the above results, when hybridomas were derived from mice immunized with isolated Vμ fragments, 6–12% of wells contained hybridomas producing antibodies against the Vμ immunogen, the parent IgM molecules, or isolated μ chains. About 30–50% of these positive wells showed antibody activities to VH determinants, 30–50% to μ chains, 0–10% to light chains, and 10–50% to idiotypic determinants. Two hybrid-containing wells were untyped; one of them, resulting from the fusion of Vμ (SA) immunized cells, produced antibody reactive with all myeloma proteins tested as well as bovine serum albumin-coated plates, and the other, formed by fusion of Vμ (NF) immunized cells, reacted with the homologous intact IgM and one of seven unrelated myeloma proteins. The latter antibody brightly stained the cytoplasm of all normal bone marrow cells, including myeloid cells, as determined by immunofluorescence.

Among 11 anti-VH wells from the fusion of Vμ (NF)-immunized cells, 6 reacted with several Vμ fragments, including homologous Vμ fragments, one with the homologous Vμ fragment only, and the other four with homologous Vμ, several intact myeloma proteins, and F(ab')2 fragments of normal IgG. Three anti-VH wells from the fusion of Vμ (MH)-immunized cells and eight anti-VH wells from the fusion of Vμ (SA)-immunized cells showed a similar spectrum of specificities within each group. Even though Vμ fragments purified by elution from an affinity column bearing homologous light chains were used as immunogens, some of the fused cells from

Table I

<table>
<thead>
<tr>
<th>Immunogen</th>
<th>Number of wells positive/total*</th>
<th>Anti-CH</th>
<th>Anti-CL</th>
<th>Anti-Id</th>
<th>Anti-VH</th>
<th>Untyped</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgMx (SA)</td>
<td>42/192</td>
<td>23</td>
<td>13</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IgDa (010)</td>
<td>34/144</td>
<td>23</td>
<td>4</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IgEA (PS)</td>
<td>26/432</td>
<td>10</td>
<td>3</td>
<td>13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>μ (007)</td>
<td>30/168</td>
<td>29</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vμ (MH)</td>
<td>10/130</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Vμ (SA)</td>
<td>16/264</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Vμ (NF)</td>
<td>27/220</td>
<td>8</td>
<td>3</td>
<td>4</td>
<td>11</td>
<td>1</td>
</tr>
</tbody>
</table>

* Positive wells contained a single heavy chain and light chain isotype and antibody activity against the immunogen.

† Specificity was determined by ELISA using plastic plates coated with 8–12 different antigens.
immunized mice produced antibodies against light chains.

These findings indicate that, at least in our hands, hybridomas secreting anti-VH antibodies can be efficiently produced by the fusion of cells from mice immunized with isolated Vμ fragments, but not with intact Ig molecules or isolated heavy chains.

**Fine Specificity of Monoclonal Anti-VH Antibodies.** Four representative monoclonal anti-VH antibodies were prepared by recloning hybridoma clones in limiting dilution and used in this study. MH-44, NF-11, and SA-44 were derived from the fusion of cells from mice immunized with Vκ (MH), Vκ (NF), and Vκ (SA), respectively (see Table I). GB-24 was derived from the fusion of cells immunized by Vκ (GB) (not shown in Table I). The MH-44 and GB-24 monoclonal antibodies were μκ in isotype, and NF-11 and SA-44 were γκ antibodies.

To determine the VH specificity of these monoclonal antibodies, we conducted the following radioimmunoassay. Various concentrations of homologous intact IgM or isolated μ or light chains were added to wells precoated with monoclonal anti-VH antibodies. 125I-labeled monoclonal anti-human μ or 125I-labeled mixtures of monoclonal antibodies to human κ and λ chains were used to measure the bound IgM or μ chains or the bound light chains, respectively. As shown in Fig. 2, all four monoclonal anti-VH antibodies reacted well with homologous μ chains, but minimally with intact homologous IgM molecules and light chain preparations. MH-44 appeared to be reactive with the homologous IgMr (MH) at the highest concentration in this experiment. This preparation of IgMr (MH) had been stored at 4°C for several months and might have undergone a degree of spontaneous degradation. Indeed, in another experiment, freshly thawed IgMr (MH) preparations from storage at -20°C showed no reactivity with MH-44 over the same range of concentrations (data not shown). The observation that the anti-VH antibodies failed to react significantly with the homologous intact IgM and light chains was not because of binding properties of the second antibodies used in the above assay system because (a) monoclonal anti-human μ antibodies used for iodination bound to intact IgM molecules as well as to the isolated μ chains, and the same was true for a mixture of monoclonal anti-κ and anti-λ antibodies, and (b) the amounts of both 125I-labeled anti-μ and 125I-labeled anti-light chain reagents to be added were adjusted to give the same cpm to the wells precoated with intact IgM molecules. Furthermore, the wells precoated with monoclonal anti-VH antibodies (10 μg/ml) exhibited <1% binding of 125I-labeled homologous intact myeloma Ig, whereas the wells coated with monoclonal anti-Id antibodies (10 μg/ml) derived from the same fusion showed 60–70% binding.

Similarly, all four anti-VH antibodies reacted with pooled normal γ chains at different degrees but did not react with the intact IgG molecules or light chains (data not shown).

Table II shows the reactivity of these anti-VH antibodies against a panel of human myeloma heavy chains as determined by ELISA on antigen-coated plates. This assay system was usually used for screening the hybridoma clones secreting anti-VH antibodies. Their VH reaction spectra overlapped but were distinctive. MH-44 reacted with one of two VκI myeloma and one VκII myeloma heavy chains but not with four VκIII myeloma heavy chains tested. GB-24 reacted with one of two VκII myeloma and four VκIII myeloma proteins, but not with a VκI myeloma protein. Both NF-11 and SA-44 were reactive with one of two VκI myeloma and two of four VκIII myeloma heavy chains.
Fig. 2. Direct binding radioimmunoassay of monoclonal anti-VH antibodies to their homologous immunoglobulin components. The plates were precoated with the following monoclonal anti-VH antibodies (10 μg/ml). (A) MH-44, (B) GB-24, (C) NF-11, and (D) SA-44. Various concentrations of their homologous intact IgM (●), homologous μ chains (○), or homologous light chains (▲) were added. The bound IgM or μ chains were measured by 125I-labeled monoclonal anti-human μ antibodies, and the bound light chains were measured by 125I-labeled mixture of monoclonal antibodies to human κ and λ determinants.

Similar results were obtained by immunofluorescent staining for the plasma cells from patients with monoclonal gammopathies (multiple myeloma, Waldenström's macroglobulinemia, benign monoclonal gammopathy, and light chain disease) (Table III). Among 20 cases of monoclonal gammopathies, excluding light chain disease, MH-44 anti-VH antibodies were reactive with 8 cases (2α, 1β, 3γ, 2α), GB-24 with 5 cases (1μ, 1β, 3γ), NF-11 with 5 cases (2μ, 2γ, 1α), and SA-44 with 3 cases (3μ). None of the affected cells from individuals with light chain disease were VH⁺.

Taken together, these results suggest that (a) these anti-VH antibodies recognize VH determinant(s) only and not combinatorial determinants of VH and VL portions of the Ig molecules; (b) the VH reaction spectra for a panel of myeloma Ig show overlapping but distinctive patterns for the four antibodies, indicating that each sees a different VH determinant; and (c) these monoclonal antibodies recognize common VH determinant(s), the distribution of which does not conform to the conventional VH subgroup assignment.

Immunofluorescent Analysis of the Expression of VH Determinants by Normal Cells of B and T
KUBAGAWA, MAYUMI, KEARNEY, AND COOPER

TABLE II
Reactivity of Monoclonal Anti-V<sub>H</sub> Antibodies, as Determined by ELISA, Using Myeloma Heavy Chain-coated Plates

<table>
<thead>
<tr>
<th>Donor</th>
<th>Heavy chain antigen</th>
<th>V&lt;sub&gt;H&lt;/sub&gt; subgroup</th>
<th>Monoclonal anti-V&lt;sub&gt;H&lt;/sub&gt; antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>GA</td>
<td>μ</td>
<td>I</td>
<td>+ + + +</td>
</tr>
<tr>
<td>001</td>
<td>α</td>
<td>I</td>
<td>- - - -</td>
</tr>
<tr>
<td>003</td>
<td>α</td>
<td>II</td>
<td>+ - - -</td>
</tr>
<tr>
<td>SA</td>
<td>μ</td>
<td>III</td>
<td>- + + +</td>
</tr>
<tr>
<td>007</td>
<td>μ</td>
<td>III</td>
<td>- + + +</td>
</tr>
<tr>
<td>McK</td>
<td>μ</td>
<td>III</td>
<td>- + + +</td>
</tr>
<tr>
<td>PS</td>
<td>ε</td>
<td>III</td>
<td>- + - -</td>
</tr>
<tr>
<td>MH</td>
<td>μ</td>
<td>ND*</td>
<td>+ + - -</td>
</tr>
<tr>
<td>GB</td>
<td>μ</td>
<td>ND</td>
<td>+ + - +</td>
</tr>
<tr>
<td>NF</td>
<td>μ</td>
<td>ND</td>
<td>- - + +</td>
</tr>
<tr>
<td>DOS</td>
<td>μ</td>
<td>ND</td>
<td>- - - +</td>
</tr>
<tr>
<td>010</td>
<td>δ</td>
<td>ND</td>
<td>+ + - -</td>
</tr>
<tr>
<td>MG</td>
<td>γ</td>
<td>ND</td>
<td>+ + + -</td>
</tr>
</tbody>
</table>

* Not determined.

Lineages. To examine whether normal human plasma cells, lymphocytes, and pre-B cells may express the determinants recognized by these monoclonal anti-V<sub>H</sub> antibodies, indirect immunofluorescence was used. Substantial proportions of normal plasma cells from bone marrow, spleen, and tonsils were stained for their cytoplasmic Ig (cIg) with the anti-V<sub>H</sub> antibodies (Table IV). MH-44, GB-24, and NF-11 stained 24–34%, 14–24%, and 13% of the total cIg<sup>+</sup> plasma cells, respectively. SA-44 showed less reactivity with normal plasma cells (~3%). A pool of the four monoclonal anti-V<sub>H</sub> antibodies reacted with ~55% of the total plasma cells, whereas the sum of each V<sub>H</sub><sup>+</sup> frequency was 67%, suggesting overlapping V<sub>H</sub> reactivities with these antibodies. All V<sub>H</sub><sup>+</sup> plasma cells were also stained with polyvalent anti-human Ig antibodies, indicating that these anti-V<sub>H</sub> antibodies did not react with non-Ig components.

The reactivity of the anti-V<sub>H</sub> antibodies with normal plasma cells was not restricted to any particular heavy chain class or light chain type (Table V). However, NF-11 and SA-44 appeared to react with more μ<sup>+</sup> plasma cells than γ<sup>+</sup> and α<sup>+</sup> plasma cells, whereas MH-44 and GB-24 tended to react with higher proportions of the IgA plasma cells.

When viable lymphocytes obtained from normal peripheral blood were stained with anti-V<sub>H</sub> antibodies, both surface Ig-bearing (sIg<sup>+</sup>) B cells and sIg<sup>-</sup> T cells were shown to be unreactive (Table IV). The failure to stain sIg on viable B cells with anti-V<sub>H</sub> antibodies was consistent with the radioimmunoassay results (Fig. 2), indicating that the anti-V<sub>H</sub> antibodies did not bind intact Ig molecules. On the other hand, the anti-V<sub>H</sub> antibodies were reactive with surface Ig molecules after air drying and acid-alcohol fixation of the cells. The frequencies of B cell subpopulations reactive with the four monoclonal anti-V<sub>H</sub> antibodies were very similar to those observed for plasma cells. By contrast, none of the anti-V<sub>H</sub> antibodies were reactive by immunofluorescence with T cell constituents either before or after cell fixation and with or without PHA stimulation.

The monoclonal anti-V<sub>H</sub> antibodies were reactive with the intracytoplasmic μ chain
of pre-B cells in bone marrow samples from fetuses (Table IV). The frequencies of 
\( V_H^+ \) pre-B cells were three- to fivefold less than those of \( V_H^+ \) plasma cells, except with 
the SA-44 antibody.

These results indicate that the monoclonal anti-\( V_H \) antibodies can be used to detect 
heterogeneity of plasma cells, B cells, and pre-B cells, but the intact surface Ig 
molecules on viable B cells are not recognized by these antibodies without prior 
denaturation. \( V_H \) determinants could not be detected at all by immunofluorescence 
analysis of either resting or activated T cells.

Discussion

To prepare antibodies against common \( V_H \) determinants of human Ig, we used 
hybridoma-derived antibodies rather than conventional heteroantisera. When intact 
Ig molecules or isolated heavy chains were used as immunogens, we did not obtain 
antibodies that were reactive with \( V_H \) fragments or multiple heavy chain isotypes.
Monoclonal anti-\( V_H \) antibodies could be readily obtained, however, by using isolated 
\( V_H \) fragments as immunogens. Four monoclonal anti-\( V_H \) antibodies, MH-44 (\( \mu_k \)), GB-
TABLE IV
Expression of VH Determinants by Normal Human Plasma Cells, Lymphocytes, and Pre-B Cells, as Determined by Indirect Immunofluorescence

<table>
<thead>
<tr>
<th>Cell phenotype and source</th>
<th>Percent cells reactive with monoclonal anti-VH antibodies*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MH-44</td>
</tr>
<tr>
<td>cIg* plasma cells</td>
<td></td>
</tr>
<tr>
<td>Bone marrow (N = 9).§</td>
<td>34 ± 11</td>
</tr>
<tr>
<td>Spleen (N = 6)</td>
<td>33 ± 6</td>
</tr>
<tr>
<td>Tonsil (N = 4)</td>
<td>23 ± 2</td>
</tr>
<tr>
<td>sIg* B cells</td>
<td></td>
</tr>
<tr>
<td>Blood, viable (N = 5)</td>
<td>≤1.4</td>
</tr>
<tr>
<td>Blood, fixed (N = 5)</td>
<td>38 ± 7</td>
</tr>
<tr>
<td>sIg+ pre-B cells</td>
<td></td>
</tr>
<tr>
<td>Fetal bone marrow§ (N = 6)</td>
<td>10 ± 7</td>
</tr>
<tr>
<td>T cells ‡</td>
<td></td>
</tr>
<tr>
<td>Blood, unstimulated (N = 5)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Blood, PHA-stimulated (N = 3)</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

* The results are recorded as the mean ± 1 SD.
‡ The number of specimens is given in parenthesis.
§ 14-17 wk of gestation.
‡‡ T cells were stained before and after acid-alchol fixation in an attempt to detect either surface or cytoplasmic VH determinants.

TABLE V
Expression of VH Determinants by Each Class of Plasma Cells in Normal Bone Marrow Samples*

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Percent VH+ plasma cells among</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IgM*</td>
</tr>
<tr>
<td>MH-44</td>
<td>27 ± 5</td>
</tr>
<tr>
<td>GB-24</td>
<td>15 ± 2</td>
</tr>
<tr>
<td>NF-11</td>
<td>18 ± 9</td>
</tr>
<tr>
<td>SA-44</td>
<td>10 ± 6</td>
</tr>
</tbody>
</table>

* The results indicate mean ± 1 SD from five normal marrow samples.

24 (μκ), NF-11 (γκ), and SA-44 (γκ), were prepared from different fusions. The evidence that these antibodies are directed toward VH, rather than CH, VL, or CL determinants, is as follows: (a) they react with their homologous Vμ fragments and isolated μ heavy chains but not with the intact homologous IgM molecules or light chains, (b) they also react with pooled normal γ chains but not with the intact IgG molecules or light chains, and (c) their reactivities are not restricted to particular heavy chain classes. The isolated Vμ fragments are known to contain about 15 additional amino-terminal residues of the Cμ1 domain (24). However, the restriction of the reactivity of the anti-VH antibodies to certain μ chains and the fact that they react with normal γ chains and isolated heavy chains of other isotypes rules out the possibility that these antibodies recognize Cμ1 determinants. Moreover VH+ plasma cells in normal bone marrow samples were found among all major isotypes (μ, γ, α, κ) of plasma cells, as determined by immunofluorescence. These data suggest that the four monoclonal antibodies are indeed directed toward the VH determinant(s).

All four of the monoclonal anti-VH antibodies reacted with isolated heavy chains...
but not with intact, undenatured Ig molecules, a finding anticipated from the ease of producing heavy and light chain-specific antibodies directed against determinants that are not exposed on the intact molecule (36). Procedures that might be expected to cause mild denaturation exposed the "hidden" V<sub>H</sub> determinants, e.g., adherence of the myeloma protein to a plastic surface was usually sufficient to allow reactivity with the homologous anti-V<sub>H</sub> antibody that could be detected by an enzyme-linked immunosorbent assay (data not shown). Similarly, the anti-V<sub>H</sub> antibodies did not bind membrane-bound Ig molecules on viable B cells. However, when blood mononuclear cells were pretreated with an acid-alcohol fixing solution, subpopulations of B cells were detectable by immunofluorescence staining with the monoclonal anti-V<sub>H</sub> antibodies (37). The frequencies of the V<sub>H</sub><sup>+</sup> B cell subpopulations (38% MH-44<sup>+</sup>, 13% GB-24<sup>+</sup>, 22% NF-11<sup>+</sup>, 6% SA-44<sup>+</sup>) were in close agreement with the relative frequencies of the different subpopulations of V<sub>H</sub><sup>+</sup> plasma cell. Indirect immunofluorescence could also be used to detect subpopulations of human pre-B cells that contain cytoplasmic μ heavy chains only. Thus, the anti-V<sub>H</sub> antibodies can be used to identify subpopulations of B lineage cells at all stages in differentiation during which they express heavy chains.

The reactivity of the monoclonal anti-V<sub>H</sub> antibodies with isolated heavy chains of known V<sub>H</sub> subgroups did not appear to correspond to the conventional V<sub>H</sub> subgroup typing. The V<sub>H</sub> reaction spectra with a panel of myeloma heavy chains and with plasma cells from monoclonal gammopathy patients revealed overlapping but distinctive patterns for the four antibodies (Tables II and III). 3-35% of normal bone marrow plasma cells were stained by immunofluorescence with the individual anti-V<sub>H</sub> antibodies, and, when combined, they stained >50% of normal plasma cells. Although human V<sub>H</sub> allotypes have been reported (38, 39), these anti-V<sub>H</sub> antibodies are apparently not allotype-specific for the following reasons: (a) plasma cells from over 20 individuals, including Caucasians, Blacks, and Orientals, were stained with the anti-V<sub>H</sub> antibodies in similar frequencies, and (b) the monoclonal anti-human V<sub>H</sub> antibodies were also reactive with Ig heavy chains of other mammals, including mouse (manuscript in preparation). These findings, thus, suggest that our anti-V<sub>H</sub> antibodies recognize highly conserved but not subgroup-specific V<sub>H</sub> determinants and that each antibody recognizes a different V<sub>H</sub> epitope.

Our monoclonal anti-V<sub>H</sub> antibodies, thus, differ in specificity from the V<sub>H</sub> subgroup-specific antibodies reported by Natvig and his colleagues (3). The latter antibodies were raised in goats or rabbits by immunizing with intact myeloma proteins with known V<sub>H</sub> and V<sub>L</sub> subgroups. Three sets of antibodies prepared by selective adsorption were rendered specific for each human V<sub>H</sub> subgroup without overlapping reaction, and these preparations reacted with intact Ig molecules as well as isolated heavy chains. We were unable to obtain monoclonal antibodies specific for the described human V<sub>H</sub> subgroups during the course of this study, suggesting that there might be a very limited number of unique determinants on human Ig that can elicit V<sub>H</sub> subgroup-specific antibodies in the mouse. It is possible that a mixture of different monoclonal anti-V<sub>H</sub> antibodies, each of which recognizes small populations of Ig molecules, might behave as V<sub>H</sub> subgroup-specific reagents analogous to the anti-V<sub>H</sub> subgroup antisera.

Other investigators have also attempted to prepare heterologous antisera against V<sub>H</sub> framework determinants of mouse (16, 40) and human (41-45) Ig. These antisera
were raised in rabbits (16, 40-43, 45) or chickens (44) by immunizing with Fv (16) or Fab (40) fragments of mouse myeloma proteins and isolated heavy chains (41), VH fragments (42, 44, 45), or intact molecules (43) of human myelomas. After appropriate absorptions, these antisera were rendered specific for idiotypic determinants (VH-VL), including cross-reactive idiotypes, and VH framework determinants, suggesting that these contain mixtures of antibodies with different specificities toward VH or VH plus VL. All of these antisera, with one exception (16), reacted with intact Ig molecules better than with isolated heavy chains. One antiserum, anti-VH 315 (16), exhibited similar reactivity to ours, except for the fact that it also contained anti-idiotypic antibodies; our anti-VH antibodies did not recognize exposed determinants, even on the homologous myeloma molecules. Recently, rabbit antisera against similarly prepared mouse V# fragments have been characterized, and their reactivities appeared to be similar to our monoclonal anti-VH antibodies, except for their reactivity with intact Ig molecules.2

There is considerable evidence (46, 47) that T cells and their products may express idiotypic or “framework” VH determinants, suggesting that VH gene products in T cells may play an important role in antigen recognition (46, 47). It has also been reported that (a) the anti-VH 315 antibodies (16) inhibit T cell function in mice (17–19) and cross-react with antigen-specific, soluble factors of T cells (20, 21) (b) unabsorbed chicken antisera against human V# fragments stain by immunofluorescence ~30% of normal T cells (44), and (c) unabsorbed rabbit antibodies against the VH fragments of a human IgG3 myeloma also show weak reactivity by immunofluorescence with ~20% of normal T cells and may inhibit mixed lymphocyte reactions (45). In contrast, our monoclonal anti-VH antibodies appear unreactive by immunofluorescence with either surface or cytoplasmic components of both resting and activated T cells, and this is consistent with the results of others using goat anti-VH subgroup antibodies (48), rabbit anti-VH framework antibodies (42), and rabbit VH allotype antibodies (11–15). Our monoclonal anti-VH subset antibodies could be valuable reagents in the future analysis of this issue using very sensitive assays of antigen-specific, soluble factors of murine and human T cells. They also provide useful probes to analyze the expression of VH determinants produced by normal and abnormal B cells (37).

Summary

Hybridoma clones secreting antibodies against common VH determinants were readily produced by fusion of cells from mice immunized with isolated V# fragments of human immunoglobulins (Ig), but not with intact Ig molecules or isolated heavy chains. Four monoclonal antibodies to the V# fragments of different IgM paraproteins were selected for analysis: MH-44 (µK), GB-24 (µK), NF-11 (γK), and SA-44 (γK). Each antibody reacted with the homologous V# fragment, homologous µ chain, and normal γ chains, but not with the intact IgM molecules, intact IgG, or isolated light chains, as determined by radioimmunoassay. The VH reaction spectra with a panel of myeloma heavy chains showed overlapping but distinctive patterns for the four antibodies. Each of the four monoclonal anti-VH antibodies appeared to react with a different “hidden” VH determinant that is not exposed on undenatured, intact Ig

---

2 Karjalainen, K. The preparation of mouse VH fragments and the characterization of heterologous anti-mouse VH antibodies. Manuscript submitted for publication.
molecules and differs from conventional $V_H$ subgroup determinants. In immunofluorescence studies, the monoclonal anti-$V_H$ antibodies did not bind to surface Ig on viable B lymphocytes, but visibly stained subpopulations of fixed B lymphocytes, pre-B cells, and normal plasma cells. The mean frequencies of $V_H^+$ plasma cells were 30% (MH-44), 17% (GB-24), 13% (NF-11), and 3% (SA-44), and similar frequencies were obtained for the $V_H^+$ B cell subpopulations. While subpopulations of B cells could be identified at all stages in differentiation by immunofluorescence with the anti-$V_H$ antibodies, neither resting nor activated T cells expressed these $V_H$ determinants in detectable amounts.

We thank Dr. M. Weigert for helpful suggestions and criticisms, Dr. J. D. Capra and Dr. K. Ishizaka for gifts of myeloma proteins with known $V_H$ and $V_L$ subgroups, our colleagues, Dr. L. Clement and Dr. W. E. Gathings for reading the manuscript, and Mrs. Y. Kubagawa for her excellent technical assistance. We also thank Mrs. E. A. Brookshire for preparation of the manuscript.

Received for publication 26 March 1982 and in revised form 22 June 1982.

References


ANTI-HUMAN VH ANTIBODIES

Holland, Amsterdam, Netherlands. 574.


